Multiple myeloma: the bone marrow microenvironment and its relation to treatment

References

• Cancer Research UK (www.cancerresearchuk.org/cancer-info/cancerstats/types/myeloma/incidence/).
   Google Scholar
• Cancer Research UK (www.cancerresearchuk.org/cancer-info/cancerstats/types/myeloma/uk-multiple-myeloma-statistics).
   Google Scholar
• Singhal S, Mehta J. Multiple myeloma. Clin J Am Soc Nephrol 2006; 1 (6): 1322–30.
   Google Scholar
• Gertz MA, Greipp PR eds. Multiple myeloma and related plasma cell disorders. London: Springer, 2004: 97–9.
   Google Scholar
• Yang HH, Ma MH, Vescio RA, Berenson JR. Overcoming drug resistance in multiple myeloma: the emergence of therapeutic approaches to induce apoptosis. J Clin Oncol 2003; 21 (22): 4239–47.
   Google Scholar
• Manier S, Sacco A, Leleu X, Ghobrial IM, Roccaro AM. Bone marrow microenvironment in multiple myeloma progression. J Biomed Biotechnol 2012; 2012: 157496. doi:10.1155/2012/157496.
   Google Scholar
• Michigami T, Shimizu N, Williams PJ et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and a4p1-integrin enhances production of osteoclast-stimulating activity. Blood 2000; 96 (5): 1953–60.
   Google Scholar
• Sarkar A. Embryonic stem cells. Delhi: Discovery Publishing House, 2009: 241–2.
   Google Scholar
• Nakamizo A, Marini F, Amano T et al. Human bone marrow derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 2005; 65 (8): 3307–18.
   Google Scholar
• Romanov YA, Darevskaya AN, Merzlikina NV, Buravkova LB. Mesenchymal stem cells from human bone marrow and adipose tissue: isolation, characterization, and differentiation potentialities. Bull Exp Biol Med 2005; 140 (1): 138–43.
   Google Scholar
• Miao Z, Jin J, Chen L et al. Isolation of mesenchymal stem cells from human placenta: Comparison with human bone marrow mesenchymal stem cells. Cell Biol Int 2006; 30 (9): 681–7.
   Google Scholar
• Dominici M, Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells: The International Society for Cellular Therapy position statement. Cytotherapy 2006; 8 (4): 315–7.
   Google Scholar
• Pei X. Stem cell engineering the new generation of cellular therapeutics. Int J Hematol 2002; 76 (Suppl 1): 155–6.
   Google Scholar
• Beyer Nardi N, da Silva Meirelles L. Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb Exp Pharmacol 2006; (174): 249–82.
   Google Scholar
• da Silva Meirelles L, Caplan AI, Nardi NB. In search of the in vivo identity of mesenchymal stem cells. Stem Cells 2008; 26 (9): 2287–99.
   Google Scholar
• Zeng H, Zhong Q, Qin Y et al. Hypoxia-mimetic agents inhibit proliferation and alter the morphology of human umbilical cord derived mesenchymal stem cells. BMC Cell Biol 2011; 12: 32.
   Google Scholar
• Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999; 284 (5411): 143–7.
   Google Scholar
• Fibbe WE, Noort WA. Mesenchymal stem cells and hematopoietic stem cell transplantation. Ann NY Acad Sci 2003; 996: 235–44.
   Google Scholar
• Majumdar MK, Thiede MA, Haynesworth SE, Bruder SP Gerson SL. Human marrow-derived mesenchymal stem cells (MSCs) express hematopoietic cytokines and support long-term hematopoiesis when differentiated toward stromal and osteogenic lineages. J Hematother Stem Cell Res 2000; 9 (6): 841–8.
   Google Scholar
• Oshima T, Abe M, Asano J et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 2005; 106 (9): 3160–5.
   Google Scholar
• Corre J, Mahtouk K, Attal M et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia 2007; 21 (5): 1079–88.
   Google Scholar
• Reagan MR, Ghobrial IM. Multiple myeloma mesenchymal stem cells: characterisation, origin and tumor promoting effects. Clin Cancer Res 2012; 18 (2): 342–9.
   Google Scholar
• Borrello I. Can we change the disease biology of multiple myeloma? Leuk Res 2012; 36 (Suppl 1): S3–12.
   Google Scholar
• Raimondo DF, Azzaro MP, Palumbo GA et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000; 85 (8): 800–5.
   Google Scholar
• Ahsmann EJ, Lokhorst HM, Dekker AW, Bloem AC. Lymphocyte function-associated antigen-1 expression on plasma cells correlates with tumor growth in multiple myeloma. Blood 1992; 79 (8): 2068–75.
   Google Scholar
• Damiano JS, Cress AE, Hazelhurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999; 93 (5): 342–9.
   Google Scholar
• van Camp B, Durie BG, Spier C et al. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1;Leu-19). Blood 1990; 76 (2): 377–82.
   Google Scholar
• Tatsumi T, Shimazaki C, Goto H et al. Expression of adhesion molecules on myeloma cells. Jpn J Cancer Res 1996; 87 (8): 837–42.
   Google Scholar
• Ara Y, Declerk YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 2010; 46 (7): 1223–31.
   Google Scholar
• Chatterjee M, Honemann D, Lentzsch S et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood 2002; 100 (9): 3311–8.
   Google Scholar
• Ogata A, Chauhan D, Teoh G et al. IL-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade. J Immunol 1997; 159: 2212–21.
   Google Scholar
• Ni H, Ergin M, Huang Q et al. Analysis of expression of nuclear factor kappaB (NF-kappaB) in multiple myeloma: downregulation of NF-kB induces apoptosis. Br J Haematol 2001; 115: 279–86.
   Google Scholar
• Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002; 3 (3): 221–7.
   Google Scholar
• Guttridge DC, Albanese C, Reuther JY, Pestell RG, Baldwin AS Jr. NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999; 19 (8): 5785–99.
   Google Scholar
• Huang S, Pettaway CA, Uehara H, Bucana CD, Fidler IJ. Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 2001; 20 (31): 4188–97.
   Google Scholar
• Cozzolino F, Torcia M, Aldinucci D et al. Production of interleukin-1 by bone marrow myeloma cells. Blood 1989; 74 (1): 380–7.
   Google Scholar
• Lee JW, Chung HY, Ehrlich LA et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 2004; 103 (6): 2308–15.
   Google Scholar
• Klein B, Zhang XG, Jourdan M et al. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood 1989; 73 (2): 517–26.
   Google Scholar
• Lichtenstein A, Berenson J, Norman D, Chang MP, Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 1989; 74 (4): 1266–73.
   Google Scholar
• Davies FE, Rollinson SJ, Rawstron AC et al. High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J Clin Oncol 2000; 18 (15): 2843–51.
   Google Scholar
• Ria R, Poccaro AM, Merchionne F, Vacca A, Dammacco F, Ribatti D. Vascular endothelial growth factor and its receptors in multiple myeloma. Leukemia 2003; 17 (10): 1961–6.
   Google Scholar
• Lentzsch S, Gries M, Janz M, Bargou R, Dorken B, Mapara MY. Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells. Blood 2003; 101 (9): 3568–73.
   Google Scholar
• Wallace SR, Oken MM, Lunetta KL, Panaskaltsis-Mortari A, Masellis AM. Abnormalities of bone marrow mesenchymal stem cells in multiple myeloma patients. Cancer 2001; 91 (7): 1219–30.
   Google Scholar
• Bataille R, Jourdan M, Zhang X, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflection of disease severity in plasma cell dyscrasias. J Clin Invest 1999; 84: 2008–11.
   Google Scholar
• Scheller J, Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol 2006; 195 (4): 173–83.
   Google Scholar
• Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 2006; 42: 1564–73.
   Google Scholar
• Catlett-Falcone R, Landowski TH, Oshiro MM et al. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999; 10: 105–15.
   Google Scholar
• Arden N, Betenbaugh MJ. Life and death in mammalian cell culture: strategies for apoptosis inhibition. Trends Biotechnol 2004; 22 (4): 174–80.
   Google Scholar
• Osaki M, Oshimura M, Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004; 9 (6): 667–76.
   Google Scholar
• Brady HJM. Apoptosis methods and protocols. London: Springer, 2004: 169–77.
   Google Scholar
• Liang J, Slingerland JM. Multiple roles of P13K/PKB (AKt) pathway in cell cycle progression. Cell Cycle 2003; 2 (4): 339–45.
   Google Scholar
• Hu L, Shi Y, Hsu J, Gera J, Ness BV, Lichtenstein A. Downstream effectors of oncogenic ras in multiple myeloma cells. Blood 2003; 101 (8): 3126–35.
   Google Scholar
• Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89 (2): 309–19.
   Google Scholar
• Kong YY, Yoshida H, Sarosi I et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 387 (6717): 315–23.
   Google Scholar
• Bucay N, Sarosi I, Dunstan CR et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 1998; 12 (9): 1260–8.
   Google Scholar
• Mizuno A, Amizuka N, Irie K et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 1998; 247 (3): 610–5.
   Google Scholar
• Terpos E, Szydlo R, Apperley JF et al. Soluble receptor activator of nuclear factor kB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 2003; 102 (3): 1064–9.
   Google Scholar
• Standal T, Seidel C, Hjertner O et al. Osteoprotegerin is bound internalised and degraded by multiple myeloma cells. Blood 2002; 100 (8): 3002–7.
   Google Scholar
• Dib IE, Gressier M, Salle V, Mentaverri R, Brazier M, Kamel S. Multiple myeloma cells directly stimulate bone resorption in vitro by down-regulating mature osteoclast apoptosis. Leuk Res 2008; 32 (8): 1279–87.
   Google Scholar
• Abe M. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int J Hematol 2011; 94: 334–43.
   Google Scholar
• Ehrlich LA, Chung HY, Ghobrial I et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 2005; 106 (4): 1407–14.
   Google Scholar
• Choi SJ, Cruz JC, Craig F et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000; 96 (2): 671–5.
   Google Scholar
• Han J, Choi SJ, Kurihara N, Koide M, Oba Y, Roodman GD. Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood 2001; 97 (11): 3349–53.
   Google Scholar
• Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 2003; 123: 106–9.
   Google Scholar
• Hjorth-Hansen H, Seifert MF, Borset M et al. Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 1999; 14 (2): 256–63.
   Google Scholar
• Gilbert L, He X, Farmer P et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000; 141 (11): 3956–64.
   Google Scholar
• Krishnan V, Bryant HU, MacDougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest 2006; 116 (5): 1202–9.
   Google Scholar
• Derksen PWB, Tjin E, Meijer HP et al. Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 2004; 101 (16): 6122–7.
   Google Scholar
• Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001; 1 (3): 222–31.
   Google Scholar
• Specht K, Haralambieva E, Bink K et al. Different mechanisms of cyclin D1 overexpression in multiple myeloma revealed by fluorescence in situ hybridization and quantitative analysis of mRNA levels. Blood 2004; 104 (4): 1120–6.
   Google Scholar
• Edwards CM, Edwards JR, Lwin TS et al. Increasing Wnt signalling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumour burden in bone in vivo. Blood 2008; 111 (5): 2833–42.
   Google Scholar
• Tian E, Zhan F, Walker R. The role of the Wnt-signaling antagonist Dkk1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483–94.
   Google Scholar
• Kaiser M, Mieth M, Liebisch P et al. Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma. Eur J Haematol 2008; 86: 490–4.
   Google Scholar
• Silvestris F, Cafforio P Tucci M, Grinello D, Dammacco F. Upregulation of osteoblasts apoptosis by malignant plasma cells a role in myeloma bone disease. Br J Haematol 2003; 122: 39–52.
   Google Scholar
• Giuliani N, Colla S, Morandi F et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005; 106 (7): 2472–83.
   Google Scholar
• Solly S. Remarks on the pathology of mollities ossium; with cases. Med Chir Trans 1844; 27: 435–98.8.
   Google Scholar
• Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348 (19): 1875–83.
   Google Scholar
• Alexanian R, Haut A, Khan AU et al. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208 (9): 1680–5.
   Google Scholar
• San Miguel JF, Creixenti JB, Garcia-Sanz R. Treatment of multiple myeloma. Haematologica 1999; 84: 36–58.
   Google Scholar
• Alexanian R, Dimopoulos MA, Delasalle K, Barlogie B. Primary dexamethasone treatment of multiple myeloma. Blood 1992; 80 (4): 887–90.
   Google Scholar
• Chauhan D, Hideshima T, Pandey P et al. RAFTK/PYK2-dependent and-independent apoptosis in multiple myeloma cells. Oncogene 1999; 18 (48): 6733–40.
   Google Scholar
• Palumbo A, Anderson K. Multiple myeloma. N Engl J Med 2011; 364 (11): 1046–60.
   Google Scholar
• Kumar S, Rajkumar SV. Thalidomide and lenalidomide in the treatment of multiple myeloma. Eur J Cancer 2006; 42 (11): 1612–22.
   Google Scholar
• Rajkumar SV, Leong T, Roche PC et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6 (8): 3111–6.
   Google Scholar
• D’Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91 (9): 4082–5.
   Google Scholar
• Kenyon KM, Browne F, D’Amato RJ. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997; 64 (6): 971–8.
   Google Scholar
• Geitz AH, Handta S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996; 31 (2–3): 213–21.
   Google Scholar
• Weber D, Rankin K, Gavino M, Delasalle K, Alexanian R. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21 (1): 16–9.
   Google Scholar
• Rajkumar SV, Rosinol L, Hussein M et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008; 26 (13): 2171–7.
   Google Scholar
• Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC. Thalidomide and lenolidomide: mechanism based drug combinations. Leuk Lymphoma 2008; 49 (7): 1238–45.
   Google Scholar
• Corral LG, Haslett PA, Muller GW et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999; 163 (1): 380–6.
   Google Scholar
• Palumbo A, Hajek R, Delforge M et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366 (19): 1759–69.
   Google Scholar
• Berenson JR, Hillner BE, Kyle RA et al. American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma. J Clin Oncol 2002; 20 (17): 3719–36.
   Google Scholar
• Hiroi-Furuya E, Kameda T, Hiura K et al. Etidronate (EHDP) inhibits osteoclastic-bone resorption, promotes apoptosis and disrupts actin rings in isolate-mature osteoclasts. Calcif Tissue Int 1999; 64 (3): 219–23.
   Google Scholar
• Terpos E, Sezer O, Croucher P et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann Oncol 2009; 20 (8): 1303–17.
   Google Scholar
• Corso A, Ferretti E, Lunghi M et al. Zoledronic acid down-regulates adhesion molecules of bone marrow stromal cells in multiple myeloma: a possible mechanism for its antitumor effect. Cancer 2005; 104 (1): 118–25.
   Google Scholar
• Kostenuik PJ. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res 2008; 24 (2): 182–95.
   Google Scholar
• Henry DH, Costa L, Goldwasser F et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29 (9): 1125–32.
   Google Scholar
• Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on denosumab. J Oral Maxillofac Surg 2010; 68 (5): 959–63.
   Google Scholar
• Dimopoulos MA, Kastritis E, Anagnostopoulos A et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2009; 91 (7): 968–71.
   Google Scholar
• Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003; 29 (Suppl 1): 3–9.
   Google Scholar
• Roccaro AM, Hideshima T, Raje N et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006; 66 (1): 184–91.
   Google Scholar
• Voorhees PM, Dees EC, O’Neil B, Orlowski RZ. The proteasome as a target for cancer therapy. Clin Cancer Res 2003; 9 (17): 6316–25.
   Google Scholar
• Fahy BN, Schlieman MG, Mortenson MM, Virudachalam S, Bold RJ. Targeting BCL-2 overexpression in various human malignancies through NF-kappaB inhibition by the proteasome inhibitor bortezomib. Cancer Chemother Pharmacol 2005; 56: 46–54.
   Google Scholar
• Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001; 20 (33): 4519–27.
   Google Scholar
• Giuliani N, Morandi F, Tagliaferri S et al. The proteasome inhibitor bortezomib affects osteoblast differentiation in vitro and in vivo in multiple myeloma patients. Blood 2007; 110 (1): 334–8.
   Google Scholar
• Qiang Y, Hu B, Chen Y et al. Bortezomib induces osteoclast differentiation via Wnt-independent activation of beta-catenin/TCF signaling. Blood 2009; 113 (18): 4319–30.
   Google Scholar
• Terpos E, Heath DJ, Rahemtulla A et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006; 135 (5): 688–92.
   Google Scholar
• Mateos MV, Hernandez JM, Hernandez MT et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006; 108 (7): 2165–72.
   Google Scholar
• Usmani SZ, Chiosis G. HSP90 Inhibitors as therapy for multiple myeloma. Clin Lymphoma Myeloma Leuk 2011; 11 (Suppl 1): S77–81.
   Google Scholar
• Pearl LH, Prodromou C, Workmann P The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008; 410 (3): 439–53.
   Google Scholar
• Basso AD, Solit DB, Gabriela C, Giri B, Tsichlis P Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002; 277 (42): 39858–66.
   Google Scholar
• Nimmanapalli R, O’Bryan E, Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001; 61 (5): 1799–804.
   Google Scholar
• Pandey P Saleh A, Nakazawa A et al. Negative regulation of cytochrome C-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90. EMBO J 2000; 19 (16): 4310–22.
   Google Scholar
• Richardson PG, Mitsiades CS, Laubach JP, Lonial S, Chanan-Khan AA, Anderson KC. Inhibition of heat shock protein 90 (Hsp90) of a therapeutic strategy for the treatment of myeloma and other cancers. Br J Haematol 2011; 152 (4): 367–79.
   Google Scholar
• Ishii T, Seike T, Nakashima T et al. Anti-tumor activity against multiple myeloma by a combination of KW-2478 an Hsp90 inhibitor with bortezomib. Blood Cancer J 2012; 2 (4): e68.
   Google Scholar
• Blade J, Esteeve J. Treatment approaches for relapsing and refractory myeloma. Acta Oncol 2000; 39 (7): 843–7.
   Google Scholar
• Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res 1991; 51 (3): 995–1002.
   Google Scholar
• Borst P, Evers R, Kool M, Wijnholds J. A family of drug transporters: the multi-drug resistance-associated proteins. J Natl Cancer Inst 2000; 92 (16): 1295–302.
   Google Scholar
• Schwarzenbach H. Expression of MRD1/P-glycoprotein, the multidrug resistance protein MRP, and the lung-resistance protein LRP in multiple myeloma. Med Oncol 2002; 19 (2): 87–104.
   Google Scholar
• Catley L, Tai Y, Chauhan D, Anderson KC. Perspectives for combination chemotherapy to overcome drug resistant multiple myeloma. Drug Resist Updat 2005; 8 (4): 205–18.
   Google Scholar
• Cancer Research UK (www.cancerresearchuk.org/cancer-info/cancerstats/types/myeloma/survival/#1_5_10_yr_survival).
   Google Scholar